6 results

Medicines for Ireland says the generic substitution and reference pricing regime has delivered savings of €1.6 billion to the State since 2013. Photograph: Russell Boyce/Reuters

(...) medicines bill by failing to encourage competition by generic and biosimilar drugs, an industry group says(...)

Patent protection rules that curb competition for medicines in markets outside the European Union should be changed, the European commission has proposed. Photograph: Julien Behal/PA Wire

(...) it might already have expired. Generics and biosimilar manufacturers, which produce “me too(...)

Sources in the pharmaceutical sector say a further 14 novel drugs were coming through the approvals system but there appeared to be no scope in the medicines budget to pay for them

(...) biosimilar drugs, come as a growing number of cutting-edge drugs are marooned at the desk of Minister for(...)

Pfizer’s  Enbrel lost patent protection in Europe earlier this year. Biogen introduced Benepali into the Irish market in September

(...) arrival in the Irish market of a competing “biosimilar” drug Benepali from Biogen. The price drop is the(...)

Where a generic medicine is a cheaper identical “copy” of a branded traditional small molecule drug, biosimilar are “me-too” versions of modern, large molecule complex biologic medicines

Switching from a branded biologic drug to a cheaper “biosimilar” makes no meaningful difference to(...)

Novartis kicked off a new era in US medicine on Thursday with the launch of the first “biosimilar(...)